Immunity: Chapter 06, B Cells and Humoral Immunity

Table of Contents

1. 6-1 Structure of Antibodies
2. 6-2 Structural Properties of Antibodies
3. 6-3 Effector Functions of Antibodies
4. 6-4 Monoclonal Antibodies
5. 6-5 Antibody-Based Methods: Radioimmunoassay and Hemagglutination
6. 6-6 Antibody-Based Methods: ELISA, Immunoblotting and FACS
7. 6-7 Antigen Receptors of B Lymphocytes
8. 6-8 B Cell Antigen Receptor Signaling and B Cell Coreceptors
9. 6-9 Early and T Cell-Independent Antibody Responses by B Cells
10. 6-10 Initiation of T Cell-Dependent Antibody Responses
11. 6-11 Hypermutation and Isotype Switching in the Germinal Center
12. 6-12 Selection and Differentiation of B Cells in the Germinal Center

6-4 Monoclonal Antibodies

Work through the following questions, checking all the correct answers. For each question there may be more than one correct answer.

1

Which of the following statements are true? a) Polyclonal antibodies cannot be used for therapeutic purposes in humans. b) Monoclonal antibodies are often produced by fusing a normal B cell to a plasmacytoma cell line to generate a hybridoma that secretes the monoclonal antibody. c) CD molecules are identified by the use of monoclonal antibodies. d) Mouse monoclonal antibodies can generally be used repeatedly in individual patients without inducing an immune response to the therapeutic antibody. e) Humanized monoclonal antibodies can be produced in mice. f) Monoclonal antibodies can be produced in effectively unlimited quantities. g) In a hybridoma, the B cell partner provides the genes encoding the immunoglobulin of interest and the plasmacytoma cell line partner provides unlimited growth. h) Humanized monoclonal antibodies are made by molecular biological techniques in which the VL and VH of a mouse monoclonal antibody are replaced with corresponding regions of a human antibody. CorrectWrong: b, c, e, f, g are correct.Your answer has been saved.